

CSL™ ASX Announcement

For immediate release

PROPOSED ACQUISITION OF TALECRIS BIOTHERAPEUTICS – MARKET SPECULATION

Melbourne, Australia (7 May 2009) - CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics, Inc. This matter is currently being considered by the U.S. Federal Trade Commission (FTC), including the potential for remedies. This development is not unusual and provides no indication that the deal will, or will not, proceed, or the timing of an FTC decision.

CSL will immediately notify the Australian Stock Exchange as and when it is aware of the decision by the FTC.

For more information about CSL Limited, visit www.csl.com.au

Investor Contact:

Mark Dehring

Director of Investor Relations

Phone: 61 3 9389 2818

Email: mark.dehring@csl.com.au